Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Boosting Bacteroides vulgatus in diabetic mice increased GLP-1 secretion, improving blood sugar control and reducing sugar ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

How Genetic Factors Are Associated with Behavioral Side Effects of GLP-1 Weight Loss Medication Glucagon-like peptide 1 ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

Media maven Oprah Winfrey stirred controversy during a recent “The Oprah Podcast” episode with Yale University obesity medicine physician Dr.

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.